<table>
<thead>
<tr>
<th>Patología</th>
<th>IFDE4</th>
<th>anti-TNF</th>
<th>anti-IL12/23</th>
<th>anti-IL17RA</th>
<th>anti-IL17A</th>
<th>ANTI-IL23p19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psoriasis</td>
<td>APR</td>
<td>ADA</td>
<td>ETA</td>
<td>INF</td>
<td>CER</td>
<td>UST</td>
</tr>
<tr>
<td>Artículos</td>
<td>3-4</td>
<td>17-20</td>
<td>36-40</td>
<td>54-56</td>
<td>67-68</td>
<td>80-82</td>
</tr>
<tr>
<td>APs</td>
<td>Ensayos clínicos</td>
<td>5-9</td>
<td>21-22</td>
<td>34,41-42</td>
<td>57</td>
<td>69-71</td>
</tr>
<tr>
<td>Artículos</td>
<td>10-11</td>
<td>23-25</td>
<td>39,43</td>
<td>58-59</td>
<td>72</td>
<td>85-86</td>
</tr>
<tr>
<td>EspA axial No-Rx</td>
<td>Ensayos clínicos</td>
<td>-</td>
<td>26</td>
<td>44</td>
<td>60</td>
<td>73-74</td>
</tr>
<tr>
<td>Artículos</td>
<td>-</td>
<td>27</td>
<td>45</td>
<td>61</td>
<td>75-76</td>
<td>86,88</td>
</tr>
<tr>
<td>EspA axial Rx</td>
<td>Ensayos clínicos</td>
<td>12</td>
<td>28-29</td>
<td>46-48</td>
<td>62</td>
<td>74</td>
</tr>
<tr>
<td>Artículos</td>
<td>-</td>
<td>30</td>
<td>49-50</td>
<td>63</td>
<td>76</td>
<td>86,88</td>
</tr>
</tbody>
</table>

**Tabla suplementaria 1.** Enumeración bibliográfica de las referencias de ensayo clínicos y artículos de la tabla 5 (ver listado referencias).


38. van de Kerkhof PCM, Segaert S, Lahfa M, Luger TA, Karolýi Z, Kaszuba A, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-


44. Clinical trials.gov [Internet]. NCT01258738. Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray St [Acceso: 12 de junio de 2020]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01258738?term=NCT01258738&draw=2&rank=1

1328-35.


53. Clinical trials.gov [Internet]. NCT00251641. The Effects of Infliximab Versus
Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2).


90. Clinical trials.gov [Internet]. NCT02438787. A Study to Evaluate the Efficacy and Safety


97. Clinical trials.gov [Internet]. NCT02985983. A Study of KHK4827 in Subjects With Axial


103. Clinical trials.gov [Internet]. NCT02074982. Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en:


120. Clinical trials.gov [Internet]. NCT02404350. Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5). [Acceso: 12 de junio de 2020]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02404350?term=NCT02404350&draw=2&rank=1


132. Clinical trials.gov [Internet]. NCT02008916. 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients.


Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of Ann Rheum Dis. 2017; 76: 79-87.


Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Nec. Arthritis Rheumatol. 2019; 71: 599-611.


158. Clinical trials.gov [Internet]. NCT03090100. A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE). [Acceso: 12 de junio de 2020]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03090100?term=NCT03090100&draw=2&rank=1


163. Clinical trials.gov [Internet]. NCT03162796. A study evaluating the efficacy and safety of guselkumab administered subcutaneously in participants with active psoriatic arthritis including those previously treated with biologic anti-tumor necrosis factor (TNF) Alpha Agent(s) (Discover-1). [Acceso: 12 de junio de 2020]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03162796?term=NCT03162796&draw=2&rank=1


175. Clinical trials.gov [Internet]. NCT02719171. BI 655066/ABBV-066/Risankizumab


177. Clinical trials.gov [Internet]. NCT03675308. A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug [Acceso: 12 de junio de 2020]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03675308?term=NCT03675308&draw=2&rank=1


